Home
Platform
- Technology
Solutions
- Clinical
- BioPharma
  - Discover BioPharma
Resources
Company
- About Us
- Leadership Team
- Investors
- Press Releases
- Blog
- Events
- Careers
- Contact
- Press Kit
- Partner With Us

Search for:

Home
Platform
- Technology
Solutions
Resources
Company
- About Us
- Leadership Team
- Investors
- Press Releases
- Blog
- Events
- Careers
- Contact
- Press Kit
- Partner With Us

Home
5

Events

Overcoming Limitations of Assessing HRR Deficiency in Somatic Samples with NGS

Turn your Sequencing Lab into a COVID-19 Research and Surveillance Powerhouse

Ensuring high resolution CNV detection

Comprehensive Profiling of Myeloid Malignancies at Moffitt Cancer Center

Our Co-Founder Lars Steinmetz at PMWC 2021 COVID: Tracking COVID-19 with a System Clinical Approach

Radiomics with AI: the key to Data-Driven Medicine in Oncology

Robust CNV detection using Whole Exome Sequencing

SOPHiA DDM™ Platform and Microsoft Azure for Genomics: when Accuracy meets Security

Garantizando la identificación de CNV de alta resolución

Implementation of a Customized Myeloid NGS-based Solution in an Academic Clinical Laboratory

A streamlined workflow for CNV analysis on whole-exome sequencing

SARS-CoV-2 : How to make the most out of your samples

« Older Entries

Next Entries »

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA Hereditary Cancer Solution, SOPHiA Myeloid Solution, SOPHiA Solid Tumor Solution are available as CE-IVD product for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).

Platform

Technology
Genomics
Radiomics
Multimodal

Clinical

Oncology
Rare and Inherited Diseases
Cardiology
Neurology
Metabolism

BioPHARMA

BioPharma

Resources

Publications
Case Studies

Company

About Us
Team
Investors
Blog, News & Events
Careers
Contact
Press Kit

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).